Recher, ChristianRöllig, ChristophBerard, EmilieBertoli, SarahDumas, Pierre-YvesTavitian, SuzanneKramer, MichaelServe, HubertBornhäuser, MartinPlatzbecker, UweMüller-Tidow, CarstenBaldus, Claudia DMartinez-Cuadron, DavidSerrano, JosefinaMartinez-Sanchez, PilarArboli, Eduardo RodriguezGil, CristinaBergua, JuanBernal, Teresade la Fuente Burguera, AdolfoDelabesse, EricBidet, AudreyPigneux, ArnaudMontesinos, Pau2023-05-032023-05-032021-09-13Récher C, Röllig C, Bérard E, Bertoli S, Dumas PY, Tavitian S, et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2022 Apr;36(4):913-922http://hdl.handle.net/10668/22599The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients ≥70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7-11.6) and 9.2 months (95% CI: 8.3-10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P < 0.0001). Treatment effect on overall survival was time-dependent. The Royston and Parmar model showed that patients treated with hypomethylating agents had a significantly lower risk of death before 1.5 months of follow-up; no significant difference between 1.5 and 4.0 months, whereas patients treated with intensive chemotherapy had a significantly better overall survival from four months after start of therapy. This study shows that intensive chemotherapy remains a valuable option associated with a better long-term survival in older AML patients.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Leukemia, myeloid, acuteRegistriesTreatment outcomeAgedAged, 80 and overAntineoplastic combined chemotherapy protocolsAzacitidineHumansRegistriesresearch article34775483open accessAncianoAzacitidinaLeucemia mieloide agudaProtocolos de quimioterapia combinada antineoplásicaResultado del tratamientoSistema de registros10.1038/s41375-021-01425-91476-5551PMC8979811https://www.nature.com/articles/s41375-021-01425-9.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979811/pdf